Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Sep;5(3):676-81.
doi: 10.1159/000341852. Epub 2012 Dec 20.

Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab

Joan Manel Gasent Blesa  1 , Sara Blasco Mollá, María Fonfría Esparcia, José Miguel Sempere Ortells, Miguel Peris Godoy, Adrian Munilla Das, Balbino Mancheño Magan, Mariano Provencio Pulla, Jose Luis Sanchez, Juan Bautista Laforga Canales, Vicente Alberola Candel
Affiliations
Case Reports

Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab

Joan Manel Gasent Blesa et al. Case Rep Oncol. 2012 Sep.

Abstract

Treatment of a relapsed glioma is a clinical challenge nowadays. New active treatments are required to treat these difficult diseases. Here we present a durable complete remission of a relapsed glioblastoma that has achieved a complete radiologic response with the combination of cetuximab and bevacizumab, in a third-line setting, that has offered a progression-free survival of 20 months. We consider here both potential mechanisms for the explanation of this result. First, the potential target of the cancer stem cells (CSCs) with these two antibodies, and second, the potential recruitment of the immune system to directly pursue the CSCs.

Keywords: Bevacizumab; Cetuximab; Durable remission; Glioma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
MRI March 2007. Initial diagnosis.
Fig. 2
Fig. 2
MRI September 2008.
Fig. 3
Fig. 3
MRI July 2009.
Fig. 4
Fig. 4
MRI February 2010.
Fig. 5
Fig. 5
MRI at relapse. February 2011.
See this image and copyright information in PMC

References

    1. Salmaggi A, Boiardi A, Gelati M, et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia. 2006;54:850–860. - PubMed
    1. Freeman CR, Perilongo G. Chemotherapy for brain stem gliomas. Childs Nerv Syst. 1999;15:545–553. - PubMed
    1. Shuper A, Kornreich L, Loven D, Michowitz S, Schwartz M, Cohen IJ. Diffuse brain stem gliomas. Are we improving outcome? Childs Nerv Syst. 1998;14:578–581. - PubMed
    1. Bouffet E, Khelfaoui F, Philip I, Biron P, Brunet-Mentigny M, Philip T. High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmacol. 1997;39:376–379. - PubMed
    1. Allen JC, Siffert J. Contemporary chemotherapy issues for children with brainstem gliomas. Pediatr Neurosurg. 1996;24:98–102. - PubMed

Publication types